| scholarly article | Q13442814 |
| P50 | author | Takao Miwa | Q91197981 |
| P2093 | author name string | Kenji Imai | |
| Koji Takai | |||
| Atsushi Suetsugu | |||
| Masahito Shimizu | |||
| Makoto Shiraki | |||
| Daisuke Taguchi | |||
| Tatsunori Hanai | |||
| P2860 | cites work | JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan | Q26797521 |
| Emerging trends in hepatocellular carcinoma incidence and mortality | Q27334932 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics" | Q28269804 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. | Q30512830 | ||
| Mechanisms to explain wasting of muscle and fat in cancer cachexia | Q34013222 | ||
| Definition and classification of cancer cachexia: an international consensus | Q34162846 | ||
| Hepatocellular carcinoma: an epidemiologic view | Q34528348 | ||
| Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma | Q34647911 | ||
| Beneficial effects of subcutaneous fat transplantation on metabolism | Q35485321 | ||
| Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment | Q35522278 | ||
| Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib | Q35722941 | ||
| Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice | Q36199751 | ||
| Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis | Q38040323 | ||
| ESPEN guidelines on definitions and terminology of clinical nutrition. | Q38819953 | ||
| ESPEN guidelines on nutrition in cancer patients. | Q38820365 | ||
| Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria | Q40592099 | ||
| Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. | Q41546596 | ||
| Sarcopenia impairs prognosis of patients with liver cirrhosis | Q41639725 | ||
| Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). | Q41642753 | ||
| Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study | Q43189703 | ||
| Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test | Q45247507 | ||
| Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study | Q45377954 | ||
| Cancer Cachexia: Beyond Weight Loss. | Q46024707 | ||
| Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). | Q47609124 | ||
| Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume | Q47631201 | ||
| Sarcopenia: origins and clinical relevance | Q48615717 | ||
| Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). | Q50969481 | ||
| Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. | Q51736029 | ||
| Abdominal fat: standardized technique for measurement at CT. | Q52911184 | ||
| Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. | Q53070653 | ||
| Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. | Q55261967 | ||
| Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients | Q57314897 | ||
| Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment | Q64226373 | ||
| Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography | Q74761237 | ||
| Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis | Q83152008 | ||
| Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge | Q84598404 | ||
| Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis | Q86720619 | ||
| Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy | Q90906677 | ||
| No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma | Q93384282 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P577 | publication date | 2019-08-19 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib | |
| P478 | volume | 11 |
| Q101038717 | Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure | cites work | P2860 |
Search more.